Global Bioinformatics Partnering Terms and Agreements 2010 to 2017

Be the first to review this product

Availability: In stock

$2,995.00

Quick Overview

The Global Bioinformatics Partnering Terms and Agreements 2010 to 2017 report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.

Global Bioinformatics Partnering Terms and Agreements 2010 to 2017
Publication date Sep 2017
Publisher Current Partnering
Number of pages 471
Report edition 2
Product code CP2111
ISBN n/a
Product type Research report
Available formats PDF

* Required Fields

$2,995.00

The Global Bioinformatics Partnering Terms and Agreements 2010 to 2017 report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.

 

  • Trends in bioinformatics partnering deals
  • Deal terms analysis
  • Partnering agreement structure
  • Partnering contract documents
  • Top deals by value
  • Most active deal makers
  • Financial deal terms for bioinformatics

 

The Global Bioinformatics Partnering Terms and Agreements 2010 to 2017 report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides a detailed understanding and analysis of how and why companies enter bioinformatics partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors bioinformatics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

This report provides details of the latest bioinformatics agreements announced in the healthcare sectors.

 

Bioinformatics is the application of computer science and information technology to the field of biology and medicine. Bioinformatics deals with algorithms, databases, information systems, web technologies, artificial intelligence, information and computation theory, software engineering, data mining, image processing, modeling, simulation, signal processing, discrete mathematics, control systems, and statistics, for generating new knowledge of biology and medicine.

 

Bioinformatics deals have increased in terms of popularity for partnering in the past decade, as computing power has been embraced in order to speed up the discovery, evaluation and clinical assessment processes.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

This report contains a comprehensive listing of all bioinformatics partnering deals announced since January 2010, including financial terms where available, including over 800 links to online deal records of actual bioinformatics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

 

The initial chapters of this report provide an orientation of bioinformatics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in bioinformatics dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

                    

Chapter 3 provides a review of the leading bioinformatics deals since 2010. Deals are listed by headline value, signed by big pharma, most active bioinformatics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

                                           

Chapter 4 provides a comprehensive listing of the top 25 most active companies in bioinformatics dealmaking with a brief summary followed by a comprehensive listing of bioinformatics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides a comprehensive and detailed review of bioinformatics partnering deals signed and announced since January 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Chapter 7 provides a comprehensive and detailed review of bioinformatics partnering deals signed and announced since Janunary 2010. The chapter is organized by specific bioinformatics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In addition, a comprehensive appendix is provided organized by bioinformatics partnering company A-Z, deal type definitions and bioinformatics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in bioinformatics partnering and dealmaking since 2010.

                                                  

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of bioinformatics technologies and products.

 

Bioinformatics Partnering Terms and Agreements provides the reader with the following key benefits:

 

• In-depth understanding of bioinformatics deal trends since 2010

• Access to headline, upfront, milestone and royalty data

• Analysis of the structure of bioinformatics agreements with numerous real life case studies

• Comprehensive access to over 800  bioinformatics deals entered into by the world’s biopharma companies

• Detailed access to actual bioinformatics contracts enter into by the leading fifty bigpharma companies

• Insight into the terms included in a bioinformatics agreement, together with real world clause examples

• Understand the key deal terms companies have agreed in previous deals

• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Bioinformatics Partnering Terms and Agreements provides the reader with the following key benefits:

 

  • In-depth understanding of bioinformatics deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of bioinformatics agreements with numerous real life case studies
  • Comprehensive access to over 800 bioinformatics deal documents entered into by the world’s biopharma companies
  • Detailed access to actual bioinformatics contracts 
  • Insight into the terms included in a bioinformatics agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in bioinformatics dealmaking

 

2.1. Introduction
2.2. Bioinformatics partnering over the years
2.3. Most active bioinformatics dealmakers
2.4. Bioinformatics partnering by deal type
2.5. Bioinformatics partnering by therapy area

2.6. Deal terms for bioinformatics partnering

2.6.1 Bioinformatics partnering headline values
2.6.2 Bioinformatics deal upfront payments
2.6.3 Bioinformatics deal milestone payments
2.6.4 Bioinformatics royalty rates

 

Chapter 3 – Leading bioinformatics deals

 

3.1. Introduction
3.2. Top bioinformatics deals by value

 

Chapter 4 – Most active bioinformatics dealmakers

 

4.1. Introduction
4.2. Most active bioinformatics dealmakers
4.3. Most active bioinformatics partnering company profiles

 

Chapter 5 – Bioinformatics contracts dealmaking directory

 

5.1. Introduction
5.2. Bioinformatics contracts dealmaking directory

 

Chapter 6 – Bioinformatics dealmaking by technology type

 

Chapter 7 – Partnering resource center

 

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

 

Appendices

 

Appendix 1 – Bioinformatics deals by company A-Z
Appendix 2 – Bioinformatics deals by stage of development
Appendix 3 – Bioinformatics deals by deal type
Appendix 4 – Bioinformatics deals by therapy area
Appendix 5 –Deal type definitions

 

About Wildwood Ventures

 

Current Partnering
Current Agreements
Recent report titles from Current Partnering



Table of figures

 

Figure 1: Bioinformatics partnering since 2010
Figure 2: Active bioinformatics dealmaking activity– 2010 to 2017
Figure 3: Bioinformatics partnering by deal type since 2010
Figure 4: Bioinformatics partnering by disease type since 2010
Figure 5: Bioinformatics deals with a headline value
Figure 6: Bioinformatics deals with an upfront value
Figure 7: Bioinformatics deals with a milestone value
Figure 8: Bioinformatics deals with a royalty rate value
Figure 9: Top bioinformatics deals by value since 2010
Figure 10: Most active bioinformatics dealmakers 2010 to 2017
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events

 

Pricing options

  • $2,995: single-user
  • $4,495: multi-user
  • $8,995: single site license
  • $14,995: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

You may also be interested in the following product(s)

Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017

Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017

$2,995.00
Global Licensing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2017

Global Licensing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2017

$2,995.00
   

Product Tags

Other people marked this product with these tags:

Use spaces to separate tags. Use single quotes (') for phrases.

© 2017 Wildwood Ventures Ltd.